IPEC's New Safety Evaluation Procedure: A Q&A with IPEC Chairman Dave Schoneker - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

IPEC's New Safety Evaluation Procedure: A Q&A with IPEC Chairman Dave Schoneker
IPEC Chairman Dave Schoneker discusses current efforts toward facilitating regulatory reviews of new excipients.

Pharmaceutical Technology
Volume 32, Issue 11

PharmTech: What can you tell us about the panel of experts involved in this review program?

Schoneker: IPEC has a new excipient evaluation procedure that we put together that allows a sponsor company to have an expert panel. The panel reviews the public and private information and develops an expert report. This expert report can be either given to a drug company in support of the use of a new excipient or a higher level of use of an existing excipient, which can be provided in the NDA or it can be incorporated into a company's drug master file (DMF). If the company felt the data, for whatever reason, was confidential and they couldn't supply it to their customer, then they could put it into a DMF with a reference to the customer who could then have FDA reference that data as part of its review. There are a couple of different mechanisms. This is a system we are working through now and starting to get usage on.

To make it even more beneficial, we are very fortunate to have the help of a key toxicologist, Dr. Robert Osterberg, who directed a group at FDA's CDER that reviewed the safety of new excipients or new excipient types at the agency. Fortunately, just as we were getting ready to roll this program out, Dr. Osterburg retired and went to work for a consulting company and we asked him to coordinate these panels.

There has been a material that has already gone through this system, and FDA said it would provide us with some feedback about the kind of report that was put together so that we would have an idea about the agency's expectations. We've done that and information about that project was provided at our IPEC conference (held in October).

Online references For more information regarding IPEC's safety evaluation process, visit the following resources:


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here